Purpose: We report our experience with the use of povidone iodine instillation into the renal pelvis for the treatment of chyluria. Materials and Methods: From August 2006 to November 2008, 26 patients with chyluria were treated. There were 18 males and 8 females ranging from 24–55 years of age. Cystoscopic localization of chylous efflux was done. Povidone iodine as a sclerosing agent was instilled through a ureteric catheter placed in the renal pelvis. A total of 9 doses were given at 8-hour intervals for 3 days. Unilateral instillation was done in 20 cases, and bilateral instillation was done in 6 patients. Results: Twenty-one of 26 patients showed complete clearance. In 4 patients, recurrence was noted and a repeat injection was given after 4 weeks, with success, in 2 patients. The other two patients required chylolymphatic disconnection. One patient was lost to follow-up. Conclusion: Our experience shows that povidone iodine is a safe and effective sclerosing agent in the management of chyluria.

Keywords:
Chyluria, Povidone iodine, Sclerosant
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.